This is a summary of the European public assessment report (EPAR) for Kyntheum. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Kyntheum. For practical information about using Kyntheum, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
Therapeutic Area (MeSH)
N/AATC Code
L04AC12
ATC Item
brodalumab
Pharmacotherapeutic Group
Immunosuppressants
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| brodalumab | N/A | 布罗利尤单抗 |
EMA Name
Kyntheum
Medicine Name
Kyntheum
Aliases
N/ANo risk management plan link.
